Lys233

Site Information
LLktAIGkAGytDkV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 10844809

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Relevant cell line - cell type - tissue:	HEK293T (epithelial) ( 7 ) , HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 , 4 ) , MV4-11 (macrophage) ( 7 ) , NCI-H929 (B lymphocyte) ( 10 ) , PC3 (prostate cell) ( 8 , 9 ) , U2OS (bone cell) ( 5 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31 23266961 Curated Info
5	Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98 23000965 Curated Info
6	Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40 21906983 Curated Info
7	Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284 21890473 Curated Info
8	Possemato A (2009) CST Curation Set: 8582; Year: 2010; Biosample/Treatment: cell line, PC3/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
9	Possemato A (2009) CST Curation Set: 8584; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
10	Possemato A (2009) CST Curation Set: 6591; Year: 2009; Biosample/Treatment: cell line, NCI-H929/MG132; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info